Telitacicept Successfully Met Primary Goal of Lowering Proteinuria in Stage A of Phase 3 Clinical Trial for IgA Nephropathy in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2025
0mins
Should l Buy VOR?
Source: Newsfilter
Clinical Trial Results: Telitacicept treatment for 39 weeks led to a significant 55% reduction in proteinuria in patients with IgA nephropathy, achieving primary and all key secondary endpoints in a Phase 3 study conducted in China.
Safety Profile: The treatment demonstrated a favorable safety profile, with most adverse events being mild or moderate, and serious adverse events occurring less frequently compared to placebo.
Regulatory Progress: A Biologics License Application (BLA) for telitacicept has been submitted in China for the treatment of IgA nephropathy, potentially marking its fifth approved indication in the country.
Company Background: Vor Bio is focused on advancing telitacicept, a dual-target fusion protein aimed at treating autoimmune diseases, with ongoing clinical trials for various conditions globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VOR
Wall Street analysts forecast VOR stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.700
Low
9.00
Averages
38.67
High
55.00
Current: 14.700
Low
9.00
Averages
38.67
High
55.00
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vor Biopharma Reports Q4 2025 Net Income Surge
- Net Income Reversal: Vor Biopharma reported a net income of $1.7228 billion for Q4 2025, a significant turnaround from a net loss of $30.7 million in Q4 2024, indicating a strong improvement in financial health that boosts investor confidence.
- Robust Cash Reserves: As of December 31, 2025, Vor Biopharma held $530.2 million in cash, cash equivalents, and marketable securities, including $75 million from a private placement in March 2026, ensuring operational funding through early 2029.
- Funding Strategy: The $75 million private placement will provide essential financial support for future R&D and operations, further advancing the company's strategic development in the biopharmaceutical sector.
- Optimistic Market Outlook: Vor Biopharma's presentations at the TD Cowen and J.P. Morgan Healthcare Conferences highlight its active engagement and recognition in the industry, signaling enhanced growth potential moving forward.
See More
RPT-VOR BIOPHARMA REPORTS Q4 NET INCOME OF USD 1,722.8 MILLION, SURPASSING IBES ESTIMATE OF USD -28.9 MILLION
- Q4 Net Income: RPT VOR Bio Pharma reported a net income of USD 1,722.8 million for the fourth quarter.
- Comparison to Estimates: This figure significantly exceeds the Ibes estimate of USD -28.9 million.
See More
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
VOR Biopharma Inc: Jefferies Begins Coverage with a Buy Rating and Sets Target Price at $50
Company Overview: Vorbio Pharma is highlighted for its innovative initiatives in the pharmaceutical sector.
Investment Rating: The company has received a "Buy" rating from Jeffries, indicating positive investor sentiment.
Target Price: Analysts have set a target price of $50 for Vorbio Pharma's stock, suggesting potential growth.
Market Position: The coverage emphasizes Vorbio's strategic positioning within the market and its future prospects.
See More
VOR Biopharma Stock Increases by 1.5% Following $75 Million Private Placement
Stock Performance: VOR BioPharma shares have increased by 1.5%.
Recent Financial Activity: The rise follows a significant private placement of $75 million.
See More
Vor Bio Secures $75M in Private Placement Financing
- Private Placement Agreement: Vor Bio has entered into a securities purchase agreement to sell 5.34 million shares at $14.05 each, expecting gross proceeds of approximately $75 million, indicating strong market confidence in its future prospects.
- Clear Use of Funds: The net proceeds from this financing will be allocated to advancing telitacicept's clinical program, including ongoing global Phase 3 trials for myasthenia gravis and primary Sjögren's disease, aimed at accelerating product commercialization.
- New Investor Participation: The financing is led by new investor TCGX, highlighting Vor Bio's success in attracting strategic investors, which strengthens its capital structure and market position.
- Positive Stock Reaction: Following the financing announcement, Vor Bio's shares rose by 4.87%, reflecting investor optimism regarding the company's growth potential, which may further enhance its market performance.
See More
Vor Biopharma Reports Q4 2025 Net Income Surge
- Net Income Reversal: Vor Biopharma reported a net income of $1.7228 billion for Q4 2025, a significant turnaround from a net loss of $30.7 million in Q4 2024, indicating a strong improvement in financial health that boosts investor confidence.
- Robust Cash Reserves: As of December 31, 2025, Vor Biopharma held $530.2 million in cash, cash equivalents, and marketable securities, including $75 million from a private placement in March 2026, ensuring operational funding through early 2029.
- Funding Strategy: The $75 million private placement will provide essential financial support for future R&D and operations, further advancing the company's strategic development in the biopharmaceutical sector.
- Optimistic Market Outlook: Vor Biopharma's presentations at the TD Cowen and J.P. Morgan Healthcare Conferences highlight its active engagement and recognition in the industry, signaling enhanced growth potential moving forward.
See More
RPT-VOR BIOPHARMA REPORTS Q4 NET INCOME OF USD 1,722.8 MILLION, SURPASSING IBES ESTIMATE OF USD -28.9 MILLION
- Q4 Net Income: RPT VOR Bio Pharma reported a net income of USD 1,722.8 million for the fourth quarter.
- Comparison to Estimates: This figure significantly exceeds the Ibes estimate of USD -28.9 million.
See More
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
VOR Biopharma Inc: Jefferies Begins Coverage with a Buy Rating and Sets Target Price at $50
Company Overview: Vorbio Pharma is highlighted for its innovative initiatives in the pharmaceutical sector.
Investment Rating: The company has received a "Buy" rating from Jeffries, indicating positive investor sentiment.
Target Price: Analysts have set a target price of $50 for Vorbio Pharma's stock, suggesting potential growth.
Market Position: The coverage emphasizes Vorbio's strategic positioning within the market and its future prospects.
See More
VOR Biopharma Stock Increases by 1.5% Following $75 Million Private Placement
Stock Performance: VOR BioPharma shares have increased by 1.5%.
Recent Financial Activity: The rise follows a significant private placement of $75 million.
See More
Vor Bio Secures $75M in Private Placement Financing
- Private Placement Agreement: Vor Bio has entered into a securities purchase agreement to sell 5.34 million shares at $14.05 each, expecting gross proceeds of approximately $75 million, indicating strong market confidence in its future prospects.
- Clear Use of Funds: The net proceeds from this financing will be allocated to advancing telitacicept's clinical program, including ongoing global Phase 3 trials for myasthenia gravis and primary Sjögren's disease, aimed at accelerating product commercialization.
- New Investor Participation: The financing is led by new investor TCGX, highlighting Vor Bio's success in attracting strategic investors, which strengthens its capital structure and market position.
- Positive Stock Reaction: Following the financing announcement, Vor Bio's shares rose by 4.87%, reflecting investor optimism regarding the company's growth potential, which may further enhance its market performance.
See More
